The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines

Clinical and Vaccine Immunology

Volumn 18, Issue 5, 2011, Pages 730-735

  Thiem, Vu Dinh ^b   Lin, Feng Ying C ^a   Canh, Do Gia ^b   Son, Nguyen Hong ^b   Anh, Dang Duc ^b   Mao, Nguyen Duc ^b   Chu, Chiayung ^a   Hunt, Steven W ^a   Robbins, John B ^a   Schneerson, Rachel ^a   Szu, Shousun C ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b MINISTRY OF HEALTH   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; DIPHTHERIA ANTIBODY; HAEMOPHILUS INFLUENZA TYPE B TETANUS TOXOID CONJUGATED VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; PSEUDOMONAS AERUGINOSA EXOPROTEIN A TYPHOID VACCINE; TETANUS ANTIBODY; TYPHOID VACCINE; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; HUMAN; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; INJECTION SITE REACTION; MALE; MATERNAL BLOOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UMBILICAL CORD BLOOD;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; FEMALE; HAEMOPHILUS VACCINES; HUMANS; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; MALE; POLYSACCHARIDES, BACTERIAL; PSEUDOMONAS AERUGINOSA; RECOMBINANT PROTEINS; TETANUS TOXOID; TYPHOID-PARATYPHOID VACCINES; VACCINES, CONJUGATE; VIETNAM; YOUNG ADULT;

EID: 79955708944     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00532-10     Document Type: Article

References (38)

1. Acharya, I. L., et al. 1986. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N. Engl. J. Med. 317:1101-1104.
2. Bell, B. P., et al. 2007. Immunogenicity of an inactivated hepatitis A vaccine in infants and young children. Pediatr. Infect. Dis. J. 26:116-122.
3. Björkholm, B., M. Granström, J. Taranger, M. Wahl, and L. Hagberg. 1995. Influence of high titers of maternal antibody on the serologic response of infants to diphtheria vaccination at three, five, and twelve months of age. Pediatr. Infect. Dis. J. 4:846-850.
4. Brooks, W. A., et al. 2005. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerg. Infect. Dis. 11:326-329.
5. Connerton, P., et al. 2000. Epidemic typhoid in Vietnam: molecular typing of multiple-antibiotic-resistant Salmonella enterica serotype Typhi from four outbreaks. J. Clin. Microbiol. 38:895-897.
6. Crump, J. A., and E. D. Mintz. 2010. Global trends in typhoid and paratyphoid fever. Clin. Infect. Dis. 50:241-246.
7. D'Angio C. T., W. M. Maniscalco, and M. E. Pichichero. 1995. Immunologic response of extremely premature infants to tetanus, Haemophilus influenzae, and polio immunizations. Pediatrics 96:18-22.
8. Fiore, A. E., et al. 2003. Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose. Pediatr. Infect. Dis. J. 22:354-359.
9. Gilman, R. H., M. Terminel, M. M. Levine, P. Hernandez-Mendoza, and R. B. Hornick. 1975. Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella typhi in typhoid fever. Lancet i:1211-1213.
10. Glezen, W. P. 2003. Effect of maternal antibodies on the infant immune response. Vaccine 21:3389-3392. (Pubitemid 36792092)
11. Hornick, R. B., et al. 1970. Typhoid fever: pathogenesis and immunologic control. N. Engl. J. Med. 283:688-691.
12. Horne, A. D. 1995. The statistical analysis of immunogenicity data in vaccine trials. A review of methodologies and issues. Ann. N. Y. Acad. Sci. 754:329-346.
13. Klugman, K. P., et al. 1987. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet ii:1165-1169. (Pubitemid 17156596)
14. Konadu, E., J. Shiloach, D. A. Bryla, J. B. Robbins, and S. C. Szu. 1996. Synthesis, characterization and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid, with emphasis on the role of O-acetyls. Infect. Immun. 64:2709-2715.
15. Kossaczka, Z., et al. 1999. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-olds in Vietnam. Infect. Immun. 67:5806-5810.
16. Kossaczka, Z., et al. 1997. Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker. Infect. Immun. 65:2088-2093.
17. Lanh, M. N., et al. 1999. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N. Engl. J. Med. 349:1390-1391.
18. Levine, M. M., et al. 1999. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 17(Suppl. 2):S22-S27. (Pubitemid 29457532)
19. Lewis, M. D., et al. 2005. Typhoid fever: a massive, single-point source, multidrug-resistant outbreak in Nepal. Clin. Infect. Dis. 40:554-561.
20. Lin, F. Y., et al. 2000. The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am. J. Trop. Med. Hyg. 62: 644-648.
21. Lin, F. Y., et al. 2001. Efficacy of a Salmonella typhi Vi conjugate vaccine (Vi-rEPA) in 2 to 5 year-old children. N. Engl. J. Med. 344:1263-1269.
22. Mermin, J. H., et al. 1999. A massive epidemic of multidrug-resistant typhoid fever in Tajikistan associated with consumption of municipal water. J. Infect. Dis. 179:1416-1422.
23. Moore, S. E., et al. 2004. Birth weight predicts response to vaccination in adults born in an urban slum in Lahore, Pakistan. Am. J. Clin. Nutr. 80:453-459.
24. Ochiai, R. L., et al. 2008. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull. World Health Organ. 86:260-268.
25. Osborn, J. J., J. Dancis, and J. F. Julia. 1952. Studies of the immunology of the newborn infant. II. Interference with active immunization by passive transplacental circulating antibody. Pediatrics 10:328-334.
26. Passwell, J. H., et al. 2010. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine 28:2231-2235.
27. Premenko-Lanier, M., et al. 2006. Maternal antibody inhibits both cellular and humoral immunity in response to measles vaccination at birth. Virology 350:429-432. (Pubitemid 43949419)
28. Santosham, M., et al. 2001. Safety and antibody persistence following Haemophilus influenzae type b conjugate or pneumococcal polysaccharide vaccines given before pregnancy in women of childbearing age and their infants. Pediatr. Infect. Dis. J. 20:931-940.
29. Sarvas, H., S. Kurikka, I. J. T. Seppälä, P. H. Mäkelä, and O. Mäkelä. 1992. Maternal antibodies partly inhibit an active antibody response to routine tetanus toxoid immunization in infants. J. Infect. Dis. 165:977-979.
30. Sinha, A., et al. 1999. Typhoid fever in children ages less than 5 years. Lancet 354:734-737. (Pubitemid 29405787)
31. Steinhoff, M. C., K. Zaman, E. Roy, R. Raqib, and E. Arifeen. 2009. Effect of maternal pneumococcal antibody on infant antibody response to Streptococcus pneumoniae conjugate vaccine (PCV7), abstr. S17. Abstr. Annu. Conf. Vaccine Res., 27 to 29 April 2009.
32. Sur, D., et al. 2009. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N. Engl. J. Med. 361:335-344.
33. Szu, S. C., A. L. Stone, J. D. Robbins, R. Schneerson, and J. B. Robbins. 1987. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J. Exp. Med. 166:1510-1524.
34. Taylor, D. N., M. M. Levine, L. Kuppens, and B. Ivanoff. 1999. Why are typhoid vaccines not recommended for epidemic typhoid fever? J. Infect. Dis. 180:2089-2090.
35. Van Savage, J., M. D. Decker, K. M. Edwards, S. H. Sell, and D. T. Karzon. 1990. Natural history of pertussis antibody in the infant and effect on vaccine response. J. Infect. Dis. 161:487-492.
36. Watson, D. C., J. B. Robbins, and S. C. Szu. 1992. Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine. Infect. Immun. 60:4679-4686.
37. Welton, J. C., J. S. Marr, and S. M. Friedman. 1979. Association between hepatobiliary cancer and typhoid carrier state. Lancet i:791-794.
38. World Health Organization. 1994. Requirements for Vi polysaccharide typhoid vaccine. Requirements for biological substances report no. 43. World Health Organ. Tech. Rep. Ser. 840:114.